DE602007009645D1 - Reagenzien und verfahren für krebsprognose und pathologische einstufung - Google Patents

Reagenzien und verfahren für krebsprognose und pathologische einstufung

Info

Publication number
DE602007009645D1
DE602007009645D1 DE602007009645T DE602007009645T DE602007009645D1 DE 602007009645 D1 DE602007009645 D1 DE 602007009645D1 DE 602007009645 T DE602007009645 T DE 602007009645T DE 602007009645 T DE602007009645 T DE 602007009645T DE 602007009645 D1 DE602007009645 D1 DE 602007009645D1
Authority
DE
Germany
Prior art keywords
reagents
methods
cancer prognosis
pathological classification
pathological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007009645T
Other languages
English (en)
Inventor
Gary Anthony Pestano
Linda Kay Samadzadeh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ventana Medical Systems Inc
Original Assignee
Ventana Medical Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventana Medical Systems Inc filed Critical Ventana Medical Systems Inc
Publication of DE602007009645D1 publication Critical patent/DE602007009645D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602007009645T 2006-02-16 2007-02-16 Reagenzien und verfahren für krebsprognose und pathologische einstufung Active DE602007009645D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77456306P 2006-02-16 2006-02-16
PCT/US2007/062362 WO2007095644A2 (en) 2006-02-16 2007-02-16 Reagents and methods for cancer prognosis and pathological staging

Publications (1)

Publication Number Publication Date
DE602007009645D1 true DE602007009645D1 (de) 2010-11-18

Family

ID=38335516

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007009645T Active DE602007009645D1 (de) 2006-02-16 2007-02-16 Reagenzien und verfahren für krebsprognose und pathologische einstufung

Country Status (10)

Country Link
US (2) US20070207489A1 (de)
EP (2) EP2290361A1 (de)
JP (1) JP5143026B2 (de)
CN (2) CN101384901A (de)
AT (1) ATE483972T1 (de)
AU (1) AU2007214427B2 (de)
CA (1) CA2642542C (de)
DE (1) DE602007009645D1 (de)
ES (1) ES2354181T3 (de)
WO (1) WO2007095644A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL282783B2 (en) 2006-05-18 2023-09-01 Caris Mpi Inc A system and method for determining a personalized medical intervention for a disease stage
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
US9697582B2 (en) 2006-11-16 2017-07-04 Visiopharm A/S Methods for obtaining and analyzing images
US8335360B2 (en) 2007-05-14 2012-12-18 Historx, Inc. Compartment segregation by pixel characterization using image data clustering
ES2599902T3 (es) 2007-06-15 2017-02-06 Novartis Ag Sistema y método de microscopio para obtener datos de muestra normalizados
CA2604317C (en) 2007-08-06 2017-02-28 Historx, Inc. Methods and system for validating sample images for quantitative immunoassays
CA2596204C (en) 2007-08-07 2019-02-26 Historx, Inc. Method and system for determining an optimal dilution of a reagent
WO2009029810A1 (en) 2007-08-31 2009-03-05 Historx, Inc. Automatic exposure time selection for imaging tissue
EP2327040B1 (de) 2008-08-15 2013-12-18 Visiopharm A/s Verfahren und system zum bestimmen eines ziels in einer biologischen probe durch bildanalyse
US8583380B2 (en) 2008-09-05 2013-11-12 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
JP5551702B2 (ja) 2008-09-16 2014-07-16 ヒストロックス，インコーポレイテッド． バイオマーカー発現の再現性のある定量
BRPI0921043A2 (pt) * 2008-11-12 2018-08-07 Caris Life Sciences Luxembourg Holdings métodos e sistemas para usar exossomas para determinar fenótipos
EP2373997A1 (de) * 2008-12-09 2011-10-12 Dako Denmark A/S Verfahren zur bewertung einer vorbehandlung
US20110306514A1 (en) 2009-01-14 2011-12-15 United States Department of Health and Human Services Ratio based biomarkers and methods of use thereof
JP5808349B2 (ja) 2010-03-01 2015-11-10 カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー セラノーシスのためのバイオマーカー
WO2011127219A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
EP2567234B1 (de) * 2010-05-07 2018-09-19 F.Hoffmann-La Roche Ag Diagnoseverfahren zum Nachweis von Zellen ex vivo
CN101876659B (zh) * 2010-06-29 2013-02-13 同济大学 用于检测肿瘤的量子点试剂盒
CA2810931C (en) 2010-09-24 2018-04-17 The Board Of Trustees Of The Leland Stanford Junior University Direct capture, amplification and sequencing of target dna using immobilized primers
US9410207B2 (en) * 2011-12-30 2016-08-09 Abbott Molecular Inc. Method and compositions for detecting epidermal growth factor receptor variant forms in cancer cells
CN106133523B (zh) * 2014-01-28 2019-06-28 奎斯特诊断投资股份有限公司 用于在癌症中检测腺瘤-腺癌过渡的方法和组合物
CN103882139B (zh) * 2014-04-04 2015-06-03 上海赛安生物医药科技有限公司 一种用于化疗方案选择的多重基因检测试剂盒
US10746740B2 (en) 2015-01-22 2020-08-18 Konica Minolta, Inc. Biological substance quantitation method, pathological diagnosis support system, and recording medium storing computer readable program
CN107688092B (zh) * 2017-08-18 2020-05-19 国家纳米科学中心 一种用于癌症患者预后评估的方法
WO2019168085A1 (ja) 2018-02-28 2019-09-06 日東紡績株式会社 固定化細胞又はｆｆｐｅ組織切片から抗原性を増強した細胞核を脱離する方法並びにそのための抗原賦活剤及びキット

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US6872817B1 (en) * 1986-01-16 2005-03-29 The Regents Of The Univ. Of California Method of staining target interphase chromosomal DNA
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5830645A (en) 1994-12-09 1998-11-03 The Regents Of The University Of California Comparative fluorescence hybridization to nucleic acid arrays
US6326148B1 (en) 1999-07-12 2001-12-04 The Regents Of The University Of California Detection of copy number changes in colon cancer
US6649359B2 (en) * 2000-06-01 2003-11-18 The Brigham & Women's Hospital, Inc. Diagnosis of endometrial precancers
CA2438112A1 (en) * 2001-02-16 2003-08-07 Immunivest Corporation Methods and reagents for the rapid and efficient isolation of circulating cancer cells
US20030190602A1 (en) * 2001-03-12 2003-10-09 Monogen, Inc. Cell-based detection and differentiation of disease states
AU2003251597A1 (en) * 2002-06-19 2004-01-06 Abgenix, Inc. Method for predicting response to epidermal growth factor receptor-directed therapy
ES2400339T3 (es) * 2002-07-15 2013-04-09 Symphony Evolution, Inc. Compuestos, composiciones farmacéuticas de los mismos y su uso en el tratamiento del cáncer
JP2006505793A (ja) * 2002-11-05 2006-02-16 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 膠芽腫の進行に関連する経路を試験するための方法及び材料
JP2007506442A (ja) * 2003-05-30 2007-03-22 ゲノミック ヘルス， インコーポレイテッド Ｅｇｆｒ阻害薬への応答に関する遺伝子発現マーカー
DE10345021A1 (de) * 2003-09-23 2005-05-04 Univ Potsdam Verfahren zur nichtinvasiven Früherkennung von Dickdarmkrebs und/oder Darmkrebsvorläuferzellen
CA2569079A1 (en) * 2004-06-03 2005-12-15 The Johns Hopkins University Methods of screening for cell proliferation or neoplastic disorders
US7932026B2 (en) * 2004-06-04 2011-04-26 Genentech, Inc. EGFR mutations
CN101438252A (zh) * 2004-10-07 2009-05-20 爱莫里大学 多功能纳米粒子共轭体及其应用
WO2011033265A1 (en) * 2009-09-18 2011-03-24 Almac Discovery Limited Pharmaceutical compounds

Also Published As

Publication number Publication date
AU2007214427B2 (en) 2011-11-10
JP5143026B2 (ja) 2013-02-13
EP1984735B1 (de) 2010-10-06
US20070207489A1 (en) 2007-09-06
ES2354181T3 (es) 2011-03-10
ATE483972T1 (de) 2010-10-15
AU2007214427A1 (en) 2007-08-23
EP2290361A1 (de) 2011-03-02
US20100184099A1 (en) 2010-07-22
EP1984735A2 (de) 2008-10-29
CN101384901A (zh) 2009-03-11
CA2642542A1 (en) 2007-08-23
CA2642542C (en) 2012-09-25
JP2009527740A (ja) 2009-07-30
WO2007095644A2 (en) 2007-08-23
CN104749378A (zh) 2015-07-01
WO2007095644A3 (en) 2007-12-27

Similar Documents

Publication Publication Date Title
DE602007009645D1 (de) Reagenzien und verfahren für krebsprognose und pathologische einstufung
DE602006002809D1 (de) Verfahren zur erkennung eines ovarialkarzinoms
DE602007003165D1 (de) Verfahren und Systeme zur Definition, Identifikation und Erfassung geometrischer Eigenschaften
WO2008154098A3 (en) Reagents and methods for mirna expression analysis and identification of cancer biomarkers
ATE535805T1 (de) Verfahren zur erkennung von autoantikörpern zur diagnostizierung und charakterisierung von erkrankungen
IN2013CN01129A (de)
HK1197275A1 (en) Multigene prognostic assay for lung cancer
ATE410524T1 (de) Verfahren und nukleinsäuren für die analyse von zellulären proliferationsstörungen
ATE513216T1 (de) Verwendung des proteins satb2 als prognostischer marker für kolorektalkarzinome
EP2074422A4 (de) Verfahren und kits für den nachweis von prostatakrebs-biomarkern
TWI317811B (de)
IL180997A0 (en) Diagnostic methods and kits utilizing platelet biomarkers for cancer
EP2177614A3 (de) Zusammensetzung und Verfahren zur Diagnose von Speiseröhrenkrebs sowie der Metastasierung von Speiseröhrenkrebs
EP2518158A4 (de) Marker für pankreaskarzinom, nachweisverfahren, kits und biochips dafür
HK1131806A1 (en) Biomarkers for prostate cancer and methods using the same
WO2009057113A3 (en) Diagnosis and prognosis of specific cancers by means of differential detection of micro-rnas/mirnas
WO2013057581A8 (en) Composite biomarker for non-invasive screening, diagnosis and prognosis of colorectal cancer
WO2006102526A3 (en) Identification of biomarkers by serum protein profiling
ATE557276T1 (de) Spezifisches verfahren zum krebsnachweis
ATE408839T1 (de) Tumor marker für urothelialen krebs
ATE534905T1 (de) Cop1-moleküle und verwendungen davon
WO2007082073A3 (en) Biomarkers for oral tongue cancer metastasis and extracapsular spread (ecs)
WO2010009074A3 (en) Method for predicting and detecting tumor metastasis
WO2008104985A3 (en) Methods for distingushing between lung squamous carcinoma and other non smallcell lung cancers
WO2009085196A8 (en) Methods and compositions for correlating genetic markers with prostate cancer risk